Clinical Efficacy of Gemcitabine plus S-1 on Refractory Nasopharyngeal Carcinoma Patients and Their Influence on Immune Function
-
摘要:目的
评价吉西他滨联合替吉奥方案治疗难治性鼻咽癌的临床疗效,及化疗前后外周血T淋巴细胞亚群的动态变化。
方法回顾性收集42例难治性鼻咽癌患者资料,给予吉西他滨联合替吉奥化疗。吉西他滨1.0 g/m2,分别于第1天和第8天静脉滴注;替吉奥40 mg/m2,口服,2次/天,d1~14。21天为1周期,所有病例均接受至少2周期化疗。收集患者化疗前后外周血,检测患者化疗前后的T细胞亚群变化。采用单因素对数秩检验(Log rank test)进行生存分析和多因素Cox比例风险回归模型分析预后因素。
结果42例患者均完成计划化疗方案和随访。其中完全缓解1例,部分缓解21例,稳定12例,进展8例,有效率为52.4%(22/42),疾病控制率为81.0%(34/42),中位疾病进展时间为6.8月,中位生存时间为14.6月。常见不良反应有骨髓抑制、胃肠道反应、皮疹、疲劳等,无治疗相关死亡。与进展组患者比较,有效组患者化疗后CD3+、CD3+CD4+细胞百分比升高,CD4+/CD8+升高。多因素分析表明是否出现肝转移是影响预后的独立危险因素。
结论吉西他滨联合替吉奥治疗难治性鼻咽癌患者疗效肯定,不良反应可以耐受,是否出现肝转移是影响预后的独立危险因素。化疗有效者外周血T淋巴细胞亚群变化更为明显。
Abstract:ObjectiveTo investigate the efficacy of gemcitabine plus S-1 on refractory nasopharyngeal carcinoma patients, and to detect the changes of T lymphocyte subsets in the peripheral blood before and after chemotherapy.
MethodsForty-two refractory nasopharyngeal carcinoma patients received gemcitabine (1.0 g/m2 on day 1 and day 8) plus oral S-1 chemotherapy (40mg/m2 twice daily, d1-14). Each cycle was repeated every 21 days, two cycles at least for each patient. The peripheral blood samples were collected before and after chemotherapy respectively, then T lymphocyte subsets were analyzed by flow cytometry. Survival analysis included univariate model and multivariate Cox regression model.
ResultsForty-two patients had completed chemotherapy and follow-up. There was one case of complete response, 21 cases of partial responses, 12 cases of stable disease, 8 cases of progressive disease, the overall response rate was 52.4%(22/42), and the disease control rate was 81.0%(34/42). Median time to progression was 6.8 months and median survival was 14.6 months. The common adverse effects were myelosuppression, gastrointestinal tract reaction, rash and fatigue; no death occurred in relation to the therapy. Compared with PD group, the percentages of CD3+, CD3+CD4+ and CD4+/CD8+ ratios were increased significantly in the response group after chemotherapy. Liver metastasis was an independent prognostic factor for overall survival.
ConclusionGemcitabine plus S-1 are an effective therapy with tolerable toxicity profile for refractory NPC patients. Liver metastasis is an independent prognostic factor for overall survival. Effective chemotherapy influences T lymphocyte subsets obviously.
-
Key words:
- Chemotherapy /
- Nasopharyngeal carcinoma /
- Gemcitabine /
- S-1 /
- Immune function /
- Prognosis
-
0 引言
胶质瘤是中枢神经系统最常见的颅内原发恶性肿瘤,在所有颅内原发性肿瘤中占70%左右,其中成年人中最常见、恶性程度最高、预后最差的肿瘤是胶质母细胞瘤(glioblastoma, GBM, WHO Ⅳ)[1]。该肿瘤具有恶性增殖和高侵袭性的特点,手术及放化疗后肿瘤复发率高。
JNK/c-Jun信号通路在调控细胞增殖、分化、凋亡和存活等基本生物学效应中扮演重要角色。JNK磷酸化下游底物c-Jun并使其激活后,可增强肿瘤细胞的增殖、侵袭和迁移能力[2-4]。MKK4和MKK7作为丝裂原活化蛋白激酶激酶(mitogen-activated protein kinase kinase, MAPKK)家族的两个成员,均可以磷酸化并激活JNK[5-7]。有报道称MKK7通过调控JNK活性调控细胞凋亡[8-10]。本课题组前期研究也发现在神经胶质瘤细胞株U251中,小分子干扰沉默MKK7表达后,可以抑制JNK/c-Jun激活[11]。为进一步了解JNK信号通路的调控机制,本研究通过采用免疫组织化学法、小分子干扰、转染及Western blot等技术检测不同组织学类型胶质瘤样本及U87细胞株中MKK7、c-Jun及其磷酸化的表达情况,分析并验证MKK7是否为直接调控JNK/c-Jun活性的关键分子。
1 资料与方法
1.1 资料
收集2015年11月—2017年11月广州医科大学附属第二医院病理科存档的胶质瘤石蜡包埋标本117例,其中92例胶质瘤和25例胶质母细胞瘤瘤旁正常脑组织。按2016年版“WHO中枢神经系统肿瘤的病理分类”,92例胶质瘤中:WHOⅡ:弥漫型星形细胞瘤15例,少突胶质细胞瘤5例;WHOⅢ:间变性星形细胞瘤11例,间变性少突胶质细胞瘤8例;WHOⅣ:胶质母细胞瘤53例(仅25例有相应的正常对照),患者临床病理特征见表 1。所有患者术前均未行放化疗,均知情同意。本研究得到医院医学伦理会审核批准。
表 1 92例胶质瘤患者临床病理特征Table 1 Clinicopathological features of 92 gliomas patients人脑胶质瘤U87细胞株购自上海细胞生物学研究所中国科学院细胞库。胎牛血清、0.25%胰酶购于美国Gibco公司。培养基高糖DMEM、转染试剂RNAi MAX、opti-MEM reduced serum medium均购于美国Invitrogen公司。MKK7-1 siRNA、MKK7-2 siRNA、MKK4 siRNA、空白对照siRNA购自上海Gene Pharma公司。anti-MKK7(#4172)、anti-MKK4(#9152)、anti-p-c-Jun(#3270)、anti-GAPDH(#2118s)均购于美国Cell Signaling Technology公司。anti-c-Jun(sc-74543)购美国Santa Cruz Biotechnology公司。
MKK4-siRNA小分子片段序列正义链:5’-GCCUUACGAAGGAUGAAUCCATT-3’,反义链:5' -UGGAUUCAUCCUUCGUAAGGCTT-3’;MKK7-siRNA1小分子片段序列正义链:5’-CCAACACGGACGUCUUCAU-3’,反义链:5’-AUGAAGACGUCCGUGUUGG-3’;MKK7-siRNA2小分子片段序列正义链:5’-GCUGGCAACAGGACAGUUU-3’,反义链:5’-AAACUGUCCUGUUGCCAGG-3’。
1.2 方法
1.2.1 免疫组织化学染色及评判标准
所有石蜡包埋病理标本均经10%中性福尔马林固定,常规HE染色组织学观察。采用Envision二步法进行免疫组织化学染色。检测标志物:MKK7、c-Jun和p-c-Jun。4 μm厚度切片经脱蜡水化和抗原修复后,滴加一抗,放入37℃水浴箱孵育60 min,PBS冲洗后按照采用Envision检测试剂盒(DAKO公司)说明书进行,室温孵育30 min,再次PBS冲洗,DAB显色,苏木精对比染色,然后脱水、透明、封片,每例均设阳性和阴性对照。按照抗体说明书分别用膀胱组织及肺癌组织作为阳性对照,另外用PBS代替一抗作为阴性对照。
免疫组织化学结果半定量判定:染色程度:基本不着色为0分;着色呈淡黄色为1分;着色呈黄色为2分;着色呈棕褐色为3分。染色阳性细胞百分比计数,计算阳性肿瘤细胞占总肿瘤细胞的比例,将其分为5个等级:着色阳性细胞占计数细胞≤5%为0分(-),5%~25%为1分(+), > 25%~50%为2分(++), > 50%~75%为3分(+++), > 75%为4分(++++)。将染色程度分级与染色细胞百分比相乘,乘积≥4分为高表达, < 4分为低表达[12-13]。
1.2.2 细胞培养、转染和Western blot检测
将U87细胞株置于10%胎牛血清、高糖DMEM液体培养液,37℃、5%CO2及饱和湿度条件下培养,每3~5天用胰酶消化传代1次,取对数生长期细胞进行实验。
于6孔板内接种对数生长期U87细胞,细胞密度为2×105个每孔,培养液为不含抗生素的DMEM培养液。待细胞生长至60%~80%融合度时,更换为不含血清的DMEM培养液,12 h后按转染试剂RNAi MAX转染方法将MKK4-siRNA、MKK7-siRNA1、MKK7-siRNA2和空白对照siRNA分别转染入U87细胞。
U87转染细胞于37℃培养箱培养48 h后,每孔2 ml PBS漂洗2遍,每孔加入150 μl IP细胞裂解液(50 mmol/L Tris, HCl pH8.0, 150 mmol/L NaCl, 1%Triton×100, 100 μg/ml PMSF),10 min后收集各组细胞。按照IP裂解液法提取细胞总蛋白,并进行BCA法测定蛋白浓度。灌制4%集成胶和10%分离胶。200 V电压电泳45 min。100 V电压转膜60 min。5%脱脂奶粉室温封闭1 h。一抗(anti-MKK4 1:1 000,anti-MKK7 1:1 000,anti-c-Jun 1:1 000,anti-p-c-Jun 1:1 000,anti-GAPDH 1:5 000)4℃孵育过夜,HRP标记抗兔或抗鼠室温孵育1 h。ECL化学发光后曝光。
1.3 统计学方法
用SPSS20.0统计分析软件包进行数据处理。多组间MKK7及p-c-Jun表达率的比较用多个样本率的χ2检验。数据以平均值±标准差(x±s)表示,多样本间比较采用单因素方差分析One-way ANOVA,两组间的比较采用独立样本t检验。相关性分析采用Spearman等级相关分析。P < 0.05为差异有统计学意义。
2 结果
2.1 c-Jun和p-c-Jun在胶质瘤及胶质母细胞瘤瘤旁正常脑组织中的表达
c-Jun和p-c-Jun阳性表达表现为细胞核内见棕黄色颗粒,见图 1。25例胶质母细胞瘤中3例(12%)c-Jun高表达,其瘤旁正常脑组织中均低表达,两者间差异无统计学意义(χ2=3.128, P=0.077),而胶质母细胞瘤中p-c-Jun高表达19例(76%),明显高于瘤旁正常脑组织6例(4%),差异有统计学意义(χ2=27.000, P=0.000)。胶质母细胞瘤中c-Jun的表达与其他类型胶质瘤无明显差异(P=0.086),但p-c-Jun表达明显升高(P=0.000),见表 2。根据WHO分级,WHO Ⅳ级胶质瘤p-c-Jun高表达率明显高于WHO Ⅱ级及WHO Ⅲ级胶质瘤(P=0.000),见图 2A,且p-c-Jun表达强度与胶质瘤WHO分级呈明显正相关(r=0.494, P=0.000)。
图 1 不同WHO分级胶质瘤及胶质母细胞瘤瘤旁正常脑组织中c-Jun、p-c-Jun、MKK7的表达Figure 1 Expression of c-Jun, p-c-Jun and MKK7 in gliomas with different WHO classification and normal brain tissues adjacent to glioblastomaA-D: c-Jun, p-c-Jun and MKK7 expression in normal brain tissues adjacent to glioblastoma; E-H: oligodendroglioma(WHO Ⅱ); I-L: anaplastic astrocytoma(WHO Ⅲ); M-P: glioblastoma (WHO Ⅳ); A, E, I, M: HE×200; B-D, F-H, J-L, N-P: IHC ×200表 2 不同组织学类型胶质瘤组织中c-Jun及p-c-Jun表达情况Table 2 c-Jun and p-c-Jun expression in different histological types of gliomas2.2 MKK7在胶质瘤及胶质母细胞瘤瘤旁正常脑组织中的表达
MKK7阳性表达表现为细胞核或质内见棕黄色颗粒,见图 1。胶质母细胞瘤中MKK7的表达高于其他类型胶质瘤及胶质母细胞瘤瘤旁正常脑组织(P=0.000),见表 3。且MKK7高表达率随着WHO分级的升高而增加(P=0.000),见图 2A。MKK7表达强度与胶质瘤WHO分级呈明显正相关(r=0.606, P=0.000)。
表 3 不同组织学类型胶质瘤及胶质母细胞瘤瘤旁正常脑组织组织中MKK7表达情况Table 3 MKK7 expression in gliomas with different histological types and normal brain tissues adjacent to glioblastoma2.3 c-Jun磷酸化与MKK7在不同WHO级别胶质瘤组织中的表达及其相关性
92例胶质瘤及25例胶质瘤母细胞瘤瘤旁正常脑组织中,48例MKK7和p-c-Jun均高表达,31例均低表达,30例MKK7高表达和p-c-Jun低表达,8例MKK7低表达和p-c-Jun高表达。根据Spearman相关分析检验,MKK7表达与c-Jun磷酸化水平正相关(r=0.387, P=0.000),见图 2B。
2.4 转染siRNA对MKK4、MKK7表达及c-Jun活性的影响
与空白对照组siRNA相比,U87细胞转染MKK4-siRNA、MKK7-siRNA1和MKK7-siRNA2可分别显著抑制MKK4(P=0.003)和MKK7(P=0.009)表达,但只有转染MKK7-siRNA可同时下调c-Jun磷酸化水平(P=0.004),见图 3。
3 讨论
c-Jun N-末端激酶(C-Jun N-terminal kinase, JNK)属于丝裂原活化蛋白激酶家族,其家族包括JNK1、JNK2和JNK3[14],其中JNK1和JNK2广泛表达于各种组织中,而JNK3主要表达于脑、心脏及睾丸等组织中[15]。JNKs参与许多生理过程,如炎性反应、细胞增殖、分化及死亡,Nacken等[16]研究表明JNK活化可促进流感病毒A(IAV)的非结构蛋白(NS1)的表达,从而诱导细胞的凋亡。而且肿瘤的发生和进展也存在JNKs的持续激活,有研究通过体内或体外实验证明多种恶性肿瘤与JNK/c-Jun的激活密切相关,如胃癌、肝癌、胰腺癌、骨肉瘤、脑肿瘤及结直肠癌等中均存在不同JNK蛋白的高表达或突变[17-20]。本研究基于免疫组织化学方法,探讨胶质瘤中c-Jun的磷酸化水平的表达情况。与正常脑组织及非胶质母细胞瘤相比,胶质母细胞瘤中磷酸化c-Jun的表达明显升高,胶质母细胞瘤的高表达率为81.1%,表明磷酸化c-Jun过表达参与了胶质母细胞瘤的发生与发展。
替莫唑胺(TMZ)是目前公认的治疗脑胶质瘤效果较好的化疗药物,然而脑胶质瘤对TMZ产生耐药性是导致化疗失败的重要原因。因此,为胶质母细胞瘤的化疗寻找新的靶点及新的化疗药物成为了胶质瘤的研究热点。有研究证明在JNK/c-Jun激活后,可以增强替莫唑胺和尼莫司汀等烷化剂等药物对胶质母细胞瘤的促凋亡作用。Tomicic等[21]发现烷基化抗癌药物作用于胶质瘤细胞LN-229后,JNK/c-Jun激活参与了晚期促凋亡反应。Ueno等[22]通过建立耐TMZ细胞模型,与对照组相比,试验组c-Jun终末激酶(JNK)的磷酸化水平增加,其下游信号通路的活性增加。上调JNK表达或siRNA特异性干扰及JNK抑制剂抑制JNK表达可以促进或抑制试验组细胞迁移及侵袭。因此,表明JNK信号通路可能成为新型治疗TMZ耐药胶质瘤的靶点。本研究也进一步证明不同级别胶质瘤c-Jun的表达水平不同,为胶质瘤的化疗,特别是TMZ耐药的处理提供了证据。
JNK/c-Jun通路的激活在胶质母细胞瘤的发生发展过程中起重要作用,但其上游调控机制并不完全清楚。JNK上游有两个MAPKK,即MKK4和MKK7。我们通过小分子干扰的方法沉默胶质瘤U87细胞株中MKK4及MKK7,发现沉默MKK7后c-Jun磷酸化水平明显下调,而沉默MKK4后c-Jun磷酸化水平无明显变化,在细胞学水平证明了MKK7是调控JNK/c-Jun活性及胶质瘤细胞增殖的关键分子。为了进一步探讨MKK7和磷酸化c-Jun的表达在胶质瘤发生发展中的关系。本研究检测了胶质母细胞瘤瘤旁正常脑组织与不同组织学类型及WHO分级的胶质瘤中MKK7和磷酸化c-Jun的表达情况,发现随着胶质瘤WHO分级的增加,MKK7及磷酸化c-Jun的高表达率明显升高;且MKK7及磷酸化c-Jun的表达正相关,进一步验证了MKK7及JNK/c-Jun通路的信号在胶质母细胞瘤发生发展的中的重要作用,为寻找胶质瘤化疗的新靶点、新化疗药物提供重要的理论依据。
-
表 1 吉西他滨联合替吉奥治疗42例难治性鼻咽癌患者的主要不良反应(n(%))
Table 1 Major adverse events of gemcitabine plus S-1 on 42 refractory nasopharyngeal carcinoma patients (n(%))
表 2 鼻咽癌组和健康志愿者组T细胞亚群检测结果(x±s, %)
Table 2 T lymphocyte subsets of refractory nasopharyngeal carcinoma patients and health volunteers (x±s, %)
表 3 疾病进展组与有效组患者T细胞亚群检测结果(x±s, %)
Table 3 T lymphocyte subsets in PD group and PR group (x±s, %)
表 4 42例难治性鼻咽癌患者单因素生存分析结果
Table 4 Univariate model analysis of overall survival of 42 refractory nasopharyngeal carcinoma patients
表 5 42例难治性鼻咽癌患者多因素分析结果
Table 5 Multivariable model analysis of overall survival of 42 refractory nasopharyngeal carcinoma patients
-
[1] Xu ZJ, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China in 2009[J]. Chin J Cancer, 2013, 32(8): 453-60. doi: 10.5732/cjc.013.10118
[2] Ma SX, Zhou T, Huang Y, et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. Ann Transl Med, 2018, 6(11): 201. http://www.nature.com/bjc/journal/v117/n12/full/bjc2017357a.html
[3] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016, 17(11): 1509-20. doi: 10.1016/S1470-2045(16)30410-7
[4] Chen C, Wang FH, An X, et al. Triplet combination with paclitaxel, cisplatin and 5-Fu is effective in metastatic and/or recurrent nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 2013, 71(2): 371-8. doi: 10.1007/s00280-012-2020-x
[5] Wu M, Ou D, He X, et al. Long-term results of a phase Ⅱ study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma[J]. Oral Oncol, 2017, 73: 118-23. doi: 10.1016/j.oraloncology.2017.08.016
[6] Peng P, Ou X, Liao H, et al. Phase Ⅱ study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy[J]. Ther Adv Med Oncol, 2016, 8(3): 153-9. doi: 10.1177/1758834016637592
[7] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-47. doi: 10.1016/j.ejca.2008.10.026
[8] Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase Ⅱ study[J]. Ann Oncol, 2002, 13(8): 1252-8. doi: 10.1093/annonc/mdf200
[9] Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054): 1883-92. doi: 10.1016/S0140-6736(16)31388-5
[10] Peng PJ, Chen H, Ou XQ, et al. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy:multi-institutional retrospective analysis[J]. Drug Des Devel Ther, 2014, 8: 1083-7. http://pubmedcentralcanada.ca/pmcc/articles/PMC4140443/
[11] 胡少轩, 何小慧, 董梅, 等.吉西他滨联合异环磷酰胺对铂类方案化疗失败的晚期鼻咽癌患者的疗效及安全性评价[J].中华肿瘤杂志, 2015, 37(8): 632-6. doi: 10.3760/cma.j.issn.0253-3766.2015.08.014 Hu SX, He XH, Dong M, et al. Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy[J]. Zhonghua Zhong Liu Za Zhi, 2015, 37(8): 632-6. doi: 10.3760/cma.j.issn.0253-3766.2015.08.014
[12] Peng PJ, Ou XQ, Chen ZB, et al. Multicenter phase Ⅱ study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy[J]. Cancer Chemother Pharmacol, 2013, 72(2): 323-8. doi: 10.1007/s00280-013-2203-0
[13] Adam JK, Odhav B, Bhoola KD. Immune responses in cancer[J]. Pharmacol Ther, 2003, 99(1): 113-32. doi: 10.1016/S0163-7258(03)00056-1
[14] Liao J, Xiao J, Zhou Y, et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma[J]. Mol Med Rep, 2015, 12(4): 6065-71. doi: 10.3892/mmr.2015.4171
[15] Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma[J]. Mol Ther, 2014, 22(1): 132-9. doi: 10.1038/mt.2013.242
[16] Wang L, Zhou D, Ren H, et al. Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer[J]. Oncol Lett, 2018, 15(6): 8635-40. http://europepmc.org/abstract/MED/29805598
[17] 聂明, 唐安洲, 黄光武, 等.鼻咽癌患者放疗前后外周血EBV-DNA和细胞免疫水平的研究[J].肿瘤防治研究, 2011, 38(4): 380-3. doi: 10.3971/j.issn.1000-8578.2011.04.005 Lie M, Tang AZ, Huang GW, et al. Research of EB virus related markers and cell immune level in peripheral blood from pre-radiotherapy and post-radiotherapy patients with nasopharyngeal carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2011, 38(4): 380-3. doi: 10.3971/j.issn.1000-8578.2011.04.005
[18] 燕翔, 赵晓, 焦顺昌, 等.晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义[J].中国肺癌杂志, 2012, 15(3): 164-71. doi: 10.3779/j.issn.1009-3419.2012.03.06 Yan X, Zhao X, Jiao SC, et al. Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2012, 15(3): 164-71. doi: 10.3779/j.issn.1009-3419.2012.03.06
[19] 徐红, 毛一香, 张学光, 等.晚期消化道肿瘤患者化疗前后T细胞亚群的变化[J].癌症, 2008, 27(4): 418-24. http://d.old.wanfangdata.com.cn/Periodical/ez200804015 Xu H, Mao YX, Zhang XG, et al. Influence of intravenous chemotherapy on cellular immunity in patients with advanced digestive tract cancer[J]. Ai Zheng, 2008, 27(4): 418-24. http://d.old.wanfangdata.com.cn/Periodical/ez200804015
[20] 汪琛, 李金高, 邹嵩, 等.初治转移性鼻咽癌预后因素及治疗模式探讨[J].中山大学学报(医学科学版), 2014, 35(6): 880-7. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201406014 Wang C, Li JG, Zou S, et al. Identify independent prognostic factors and optimize treatment of initial nasopharyngeal carcinoma with distant metastasis[J]. Zhongshan Da Xue Xue Bao(Yi Xue Ke Xue Ban), 2014, 35(6): 880-7. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201406014
[21] 唐溢聪, 卢秋霞, 招丽蓉, 等.鼻咽癌肝转移的化疗疗效及预后分析-附100例报道[J].中国癌症防治杂志, 2009, 1(3): 238-41. doi: 10.3969/j.issn.1674-5671.2009.03.15 Tang YC, Lu QX, Zhao LR, et al. Analysis of therapeutic effect and prognosis in nasopharyngeal carcinoma patients with liver metastasis treated by chemotherapy: 100 cases report[J]. Zhongguo Ai Zheng Fang Zhi Za Zhi, 2009, 1(3): 238-41. doi: 10.3969/j.issn.1674-5671.2009.03.15